Insider Selling: Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells $24,620.00 in Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma sold 2,000 shares of the company’s stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $12.31, for a total transaction of $24,620.00. Following the completion of the transaction, the president now owns 2,831,260 shares of the company’s stock, valued at $34,852,810.60. This trade represents a 0.07 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Songjiang Ma also recently made the following trade(s):

• On Monday, March 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.09, for a total transaction of $24,180.00.
• On Wednesday, March 12th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.74, for a total transaction of $23,480.00.
• On Monday, March 10th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.14, for a total transaction of $20,280.00.
• On Friday, March 7th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.25, for a total transaction of $20,500.00.
• On Monday, February 10th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.90, for a total transaction of $23,800.00.
• On Tuesday, February 4th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.62, for a total transaction of $23,240.00.
• On Wednesday, January 29th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.43, for a total transaction of $22,860.00.
• On Monday, January 27th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.18, for a total transaction of $22,360.00.
• On Thursday, January 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.49, for a total transaction of $20,980.00.
• On Tuesday, January 21st, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.85, for a total transaction of $21,700.00.

Gyre Therapeutics Trading Up 20.0 %

Shares of GYRE stock opened at $10.28 on Thursday. The company has a fifty day moving average price of $11.30 and a two-hundred day moving average price of $12.24. Gyre Therapeutics, Inc. has a one year low of $8.26 and a one year high of $19.00.

Gyre Therapeutics (NASDAQ:GYRE) last issued its quarterly earnings data on Monday, March 17th. The company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.03). The company had revenue of $27.87 million during the quarter, compared to the consensus estimate of $23.50 million. Gyre Therapeutics had a negative net margin of 84.57% and a negative return on equity of 118.43%.

Hedge Funds Weigh In On Gyre Therapeutics

Several large investors have recently modified their holdings of GYRE. Charles Schwab Investment Management Inc. raised its position in shares of Gyre Therapeutics by 392.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company’s stock valued at $1,425,000 after purchasing an additional 90,557 shares during the period. Advantage Alpha Capital Partners LP bought a new position in Gyre Therapeutics during the third quarter worth about $334,000. FMR LLC bought a new position in Gyre Therapeutics during the third quarter worth about $47,000. State Street Corp increased its position in Gyre Therapeutics by 8.8% during the third quarter. State Street Corp now owns 104,490 shares of the company’s stock worth $1,310,000 after acquiring an additional 8,412 shares during the period. Finally, Barclays PLC increased its position in Gyre Therapeutics by 281.8% during the third quarter. Barclays PLC now owns 9,288 shares of the company’s stock worth $116,000 after acquiring an additional 6,855 shares during the period. 23.99% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Noble Financial began coverage on shares of Gyre Therapeutics in a research note on Tuesday, March 11th. They issued an “outperform” rating for the company.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.